GLPwatch
Gastroparesis
0 FAERS reports across 0 drugs
Last updated 2026-05-28 15:46 UTCGastroparesis is a condition where the stomach takes too long to empty its contents, causing food to stay in the stomach longer than usual.
Plain-language definition of the term.
FDA labels for Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Wegovy, Xultophy, and Zepbound include warnings about the risk of gastroparesis, a condition that affects stomach muscle movement.
AI summary of the sources below.
FAERS report counts reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
No FAERS reports for this side effect in the current sample.
Mentioned in FDA labels
Research mentioning gastroparesis (5)
- Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
- Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
- Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.
- Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.
- Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.